US4880783A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of adenosine, hypoxanthine and ribose-containing solution for improved protection of the heart during surgery
Assignee: UVA Licensing and Ventures Group
•
Filing: 1988-09-29
•
Granted: 1989-11-14
•
Expires: 2008-09-29
Abstract
Abstract The invention relates to an improved cardioplegic solution for reducing ischemic damage to the heart during operations and/or transplantation. The invented solution contains adenosine, hypoxanthine and ribose in addition to the electrolytes contained in standard cardioplegic solutions.
Inventors
- 👤 Robert M. Mentzer, Jr.
- 👤 Stephen W. Ely
- 👤 Robert D. Lasley
- 👤 Robert M. Berne
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 02:46
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K33/00; A61P; A61P5/00; A61P5/24; A61P9/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
27 words
A heart perfusate for reducing ischemic damage to a heart isolated from a normal blood supply comprising a cardioplegic solution having at least one purine nucleoside additive.
Claim 2
Dependent Claim
27 words
A heart perfusate for reducing ischemic damage to a heart isolated from a normal blood supply comprising a cardioplegic solution having at least one purine nucleoside additive.
Claim 3
Dependent Claim
11 words
The cardioplegic solution of claim 1 wherein the additive is adenosine.
Claim 4
Dependent Claim
24 words
The cardioplegic solution of claim 1 wherein the additive is adenosine in a final concentration in the solution of about 100 μmoles per liter.
Claim 5
Dependent Claim
11 words
The cardioplegic solution of claim 1 wherein the additive is hypoxanthine.
Claim 6
Dependent Claim
24 words
The cardioplegic solution of claim 1 wherein the additive is hypoxanthine in a final concentration in the solution of about 100 μmoles per liter.
Claim 7
Dependent Claim
16 words
The cardioplegic solution of claim 1 and a sugar additive, wherein the sugar additive is ribose.
Claim 8
Dependent Claim
27 words
The cardioplegic solution of claim 1 and a sugar additive, wherein the sugar additive is ribose in a final concentration in the solution of about 2 mmolar.
Claim 9
Dependent Claim
14 words
The cardioplegic solution of claim 1 wherein the additive is adenosine, hypoxanthine and ribose.
Claim 10
Dependent Claim
53 words
The cardioplegic solution of claim 1 wherein the additive is adenosine in a final concentration in the solution of about 100 μmoles per liter, hypoxanthine in a final concentration in the solution of about 100 μmoles per liter, and ribose in a final concentration in the solution of about 2 mmoles per liter.
Claim 11
Dependent Claim
63 words
The cardioplegic solution of claim 1 wherein the additive is adenosine ina final concentration in the solution of about 100 μmoles per liter, hypoxanthine in a final concentration in the solution of about 100 μmoles per liter, and ribose in a final concentration in the solution of about 2 mmoles per liter, further comprising Na, Cl, K, Ca and Mg ions in solution.
Claim 12
Dependent Claim
95 words
The cardioplegic solution of claim 1 wherein the additive is adenosine in a final concentration in the solution of about 100 μmoles per liter, hypoxanthine in a final concentration in the solution of about 100 μmoles per liter, and ribose in a final concentration in the solution of about 2 mmoles per liter, further comprising Na, Cl, K, Ca and Mg ions in solution in the following approximate concentrations: ______________________________________
Na 110 meq/1
Cl 160 meq/1
K 16 meq/1
Ca.sup.++ 2.4 meq/1
Mg 32 meq, and
NaHCO.sub.3 or HCl to adjust pH to 7.4.
______________________________________
Claim 13
Dependent Claim
48 words
An improved method for enhancing ability of a myocardium to tolerate ischemia comprising perfusing a preischemic heart with a cardioplegic solution containing at least one purine nucleoside during either cardiovascular surgery or harvesting for cardiac transplantation, wherein the cardioplegic solution reduces the rate of ATP degradation during ischemia.
Claim 14
Dependent Claim
48 words
An improved method for enhancing ability of a myocardium to tolerate ischemia comprising perfusing a preischemic heart with a cardioplegic solution containing at least one purine nucleoside during either cardiovascular surgery or harvesting for cardiac transplantation, wherein the cardioplegic solution reduces the rate of ATP degradation during ischemia.
Claim 15
Dependent Claim
11 words
The method of claim 12 wherein the purine nucleoside is adenosine.
Claim 16
Dependent Claim
11 words
The method of claim 12 wherein the purine nucleoside is hypoxanthine.
Claim 17
Dependent Claim
15 words
The method of claim 14 further comprising perfusing the heart with a solution containing ribose.
Claim 18
Dependent Claim
23 words
The method of claim 12 wherei the at least one purine nucleoside is adenosine and hypoxanthine and wherein the solution further contains ribose.
References Cited (Backward Citations)
US2994640A
Cited
US3868451A
Cited
US3914414A
Cited
US3992531A
Cited
US4360522A
Cited
US4299832A
Cited
US4338319A
Cited
US4481197A
Cited
US4590180A
Cited
US4388308A
Cited
US4546095A
Cited
US4673563A
Cited
US4415556A
Cited
US4514405A
Cited
US4544556A
Cited
US4473571A
Cited
US4501735A
Cited
US4614732A
Cited
US4593019A
Cited
US4605644A
Cited
US4693996A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-11-13 | 1993-05-15 | 1993-11-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-11-13 | 1997-05-15 | 1997-11-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-11-13 | 2001-05-15 | 2001-11-14 | $7700.00 | Window Closed / Lapsed |